BTIG Cuts Keryx Biopharmaceuticals (KERX) to Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Roth Capital Downgrades Keryx Biopharmaceuticals (KERX) to Neutral
August 10, 2015 6:49 AM EDTRoth Capital downgraded Keryx Biopharmaceuticals (NASDAQ: KERX) from Buy to Neutral with a price target of $6.00 (from $11.00) following Q2 results, citing too much hedging.
Analyst Joseph Pantginis commented, "Following 2Q15 results, we believe Auryxia's headwinds are strong at the moment and step to the... More
Keryx Biopharma (KERX) Reports In-Line Q2 EPS
August 5, 2015 7:17 AM EDTKeryx Biopharma (NASDAQ: KERX) reported Q2 EPS of ($0.26), in-line with the analyst estimate of ($0.26). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $2.86 million.
"We are making progress on several important milestones across our business, including securing broad reimbursement for Auryxia (ferric citrate) that today enables... More
